A PHASE 1B/2A PILOT RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILLITY OF AUTOLOGOUS T-CELLS EXPRESSING ENHANCED TCRS (T-CELL RECEPTORS) SPECIFIC FOR NY-ESO-1/LAGE-1a (GSK3377794) ALONE, OR IN COMBINATION WITH PEMBROLIZUMAB IN HLA-A2+ PARTICIPANTS WITH NY-ESO-1- or LAGE-1a-POSITIVE ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER